Sign In
Buy STIM
$1.98
+0.0100 (+0.508%)
At Close: Jul 31, 2026
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 31'st Jul 2026
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
08:32am, Tuesday, 28'th Jul 2026
New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care delivery New location expands access to advanced
Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 28'th Jul 2026
MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
04:05pm, Monday, 20'th Jul 2026
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through
Why Is Neuronetics Stock Soaring Monday?
02:21pm, Monday, 20'th Jul 2026
BTIG initiated coverage of Neuronetics Inc. (NASDAQ:STIM) on Monday, noting that the company is entering a pivotal new phase as the psilocybin opportunity takes center stage.
Neuronetics: Top Line Growth, Low Valuation, But Gross Margin Struggles
08:00am, Saturday, 18'th Jul 2026
Neuronetics is revisited following prior coverage in March 2026. The article focuses on STIM's recent developments and their impact on the investment thesis. Key topics include operational progress, f
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
08:30am, Monday, 06'th Jul 2026
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through
Neuronetics Appoints Robert Greene as Senior Vice President Sales
04:30pm, Tuesday, 02'nd Jun 2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
08:32am, Tuesday, 02'nd Jun 2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
08:32am, Thursday, 14'th May 2026
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
12:41pm, Tuesday, 05'th May 2026
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
10:15am, Tuesday, 05'th May 2026
Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.21 per share a year ago.
Neuronetics Reports First Quarter 2026 Financial and Operating Results
07:50am, Tuesday, 05'th May 2026
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare c
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 29'th Apr 2026
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 21'st Apr 2026
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improv
